Return to Listing

5 result(s) for Platinol

PI Name Protocol # Title
Jeremy Cetnar IRB00011845 A phase III, open label, randomized study of MPDL3280A (anti-pdl1 antibody) compared with cisplatin or carboplatin + pemetrexed for PDL1- selected chemotherapy naive patients with stage IV non -squamous non small cell lung cancer
Khaled Tolba IRB00012012 A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of MPDL3280A (ANTI−PD-L1 ANTIBODY) Compared With Best Supportive Care Following adjuvant Cisplatin-Based Chemotherapy In PD-L1−Selected Patients With Completely Resected STAGE IB−IIIA
John Holland STUDY00015152 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Trial of the Effects of Intravenous GC4419 on the Incidence and Duration of Severe Oral Mucositis (OM) in Patients Receiving Post-Operative or Definitive Therapy with Single-Agent Cisplatin plus IMRT for Locally Advanced, Non-Metastatic Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Jeremy Cetnar STUDY00015245 S1314: A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
John Holland STUDY00015558 A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080